Literature DB >> 15374989

Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.

DeeDee K Smart1, Karen L Ortiz, David Mattson, C Matthew Bradbury, Kheem S Bisht, Leah K Sieck, Martin W Brechbiel, David Gius.   

Abstract

Redox-sensitive signaling factors regulate multiple cellular processes, including proliferation, cell cycle, and prosurvival signaling cascades, suggesting their potential as molecular targets for anticancer agents. It is logical to set constraints that a molecular target should meet at least one of the following criteria: (1) inhibition of prosurvival signaling pathways; (2) inhibition of cell cycle progression; or (3) enhancement of the cytotoxic effects of anticancer agents. Therefore, we hypothesized that thioredoxin reductase 1 (TR), a component of several redox-regulated pathways, might represent a potential molecular target candidate in response to agents that induce oxidative stress. To address this issue, permanent cell lines overexpressing either the wild-type (pCXN2-myc-TR-wt) or a Cys-Ser mutant (pCXN2-myc-mTR) TR gene were used, as were parental HeLa cells treated with 1-methyl-1-propyl-2-imidazolyl disulfide (IV-2), a pharmacologic inhibitor of TR. Cells were exposed to the oxidative stressors, H2O2 and ionizing radiation (IR), and analyzed for changes in signal transduction, cell cycle, and cytotoxicity. Analysis of HeLa cells overexpressing the pCXN2-myc-TR-wt gene showed increased basal activity of nuclear factor kappaB (NFkappaB) and activator protein (AP-1), whereas HeLa cells expressing a pCXN2-myc-mTR gene and HeLa cells treated with IV-2 were unable to induce NFkappaB or AP-1 activity following H2O2 or IR exposure. Fluorescence-activated cell sorting analysis showed a marked accumulation of pCXN2-myc-mTR cells in the late G1 phase, whereas pCXN2-myc-TR-wt cells showed a decreased G1 subpopulation. Chemical inhibition of TR with IV-2 also completely inhibited cellular proliferation at concentrations between 10 and 25 micromol/L, resulting in a G1 phase cell cycle arrest consistent with the results from cells expressing the pCXN2-myc-mTR gene. Following exposure to H2O2 and IR, pCXN2-myc-mTR- and IV-2-treated cells were significantly more sensitive to oxidative stress-induced cytotoxicity as measured by clonogenic survival assays. Finally, IV-2-treated cells showed increased tumor cell death when treated with H2O2 and IR. These results identify TR as a potential target to enhance the cytotoxic effects of agents that induce oxidative stress, including IR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374989     DOI: 10.1158/0008-5472.CAN-03-3990

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Thioredoxin reductase 1 knockdown enhances selenazolidine cytotoxicity in human lung cancer cells via mitochondrial dysfunction.

Authors:  Robyn L Poerschke; Philip J Moos
Journal:  Biochem Pharmacol       Date:  2010-10-12       Impact factor: 5.858

Review 2.  Texaphyrins: tumor localizing redox active expanded porphyrins.

Authors:  Jonathan F Arambula; Christian Preihs; Derric Borthwick; Darren Magda; Jonathan L Sessler
Journal:  Anticancer Agents Med Chem       Date:  2011-02       Impact factor: 2.505

3.  Chromosomal instability causes sensitivity to metabolic stress.

Authors:  Z Shaukat; D Liu; A Choo; R Hussain; L O'Keefe; R Richards; R Saint; S L Gregory
Journal:  Oncogene       Date:  2014-10-27       Impact factor: 9.867

4.  Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library.

Authors:  Brian E Lally; Geoffrey A Geiger; Steven Kridel; Alice E Arcury-Quandt; Michael E Robbins; Nancy D Kock; Kenneth Wheeler; Prakash Peddi; Alexandros Georgakilas; Gary D Kao; Constantinos Koumenis
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 5.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

6.  The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase.

Authors:  Jennifer D Tibodeau; Linda M Benson; Crescent R Isham; Whyte G Owen; Keith C Bible
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

7.  Thioredoxin and thioredoxin reductase influence estrogen receptor alpha-mediated gene expression in human breast cancer cells.

Authors:  Abhi K Rao; Yvonne S Ziegler; Ian X McLeod; John R Yates; Ann M Nardulli
Journal:  J Mol Endocrinol       Date:  2009-07-20       Impact factor: 5.098

8.  BAT3 and SET1A form a complex with CTCFL/BORIS to modulate H3K4 histone dimethylation and gene expression.

Authors:  Phuongmai Nguyen; Gil Bar-Sela; Lunching Sun; Kheem S Bisht; Hengmi Cui; Elise Kohn; Andrew P Feinberg; David Gius
Journal:  Mol Cell Biol       Date:  2008-09-02       Impact factor: 4.272

9.  Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells.

Authors:  Andrean L Simons; Arlene D Parsons; Katherine A Foster; Kevin P Orcutt; Melissa A Fath; Douglas R Spitz
Journal:  J Oncol       Date:  2009-09-02       Impact factor: 4.375

10.  Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues.

Authors:  Carol D Curtis; Daniel L Thorngren; Ann M Nardulli
Journal:  BMC Cancer       Date:  2010-01-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.